Expired activity
Please go to the PowerPak homepage and select a course.

Expanding Horizons in Immuno-Oncology: Health System Pharmacists' Perspectives –
Case 1: The New Immune Checkpoint Inhibitors: Toward a Cure for Metastatic Melanoma

Provided by The University of Tennessee College of Pharmacy, in cooperation with ASiM.
Supported by an educational grant from Bristol-Myers Squibb Company.


In the past several years, the introduction of breakthrough therapies has revolutionized the treatment of patients with metastatic melanoma. These drugs work on T-lymphocytes to prevent 2 key immune checkpoints from blocking their actions. This learning initiative addresses this new class of treatment, which has been shown to dramatically improve both patient response and survival; this case activity will help guide pharmacists, especially those working in healthcare systems, to better treat patients with metastatic melanoma. A review of the emerging knowledge regarding the immunology of metastatic melanoma and the new immune checkpoints that have been developed, which enable the patient's immune system to overcome the normal inhibitory pathways that maintain self-tolerance, will be conducted. Key safety issues associated with these therapies will also be addressed. Ultimately, this module will help pharmacists to better understand their role in the treatment of patients with this serious, but now more treatable, cancer.


The goal of this learning initiative is to improve pharmacists' understanding of the immunology of metastatic melanoma, the safety and efficacy of the novel immune checkpoint inhibitors, and their role in the treatment paradigm.


This enduring case activity is designed for health-system pharmacists. No prerequisites required.


The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. At the conclusion of this activity, the participant should be able to:

  • Explain how the new checkpoint inhibitors offer an innovative approach to promoting an immune response in patients with metastatic melanoma.
  • Assess the efficacy and safety of the several approved immunotherapeutics as mono- or combination-therapy regimens.
  • Manage the specific immune-related toxicities associated with the use of anti-CTLA-4 and anti-PD-1 drugs.


acpeThe University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based program will provide a statement for 0.5 contact hours of credit (0.5 CEUs) and will be available at the completion of the activity. Successfully completing the activity and receiving credit includes: 1) attending the session; 2) watching, listening to, and participating in the educational activity; 3) completing the self-assessment instrument with a score of at least 70%. CE credit will be submitted to the NABP CE Monitor. UAN: 0064-0000-16-210-H01-P. CE credit will be submitted to the NABP CPE Monitor within 30 days.  It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.


Your CE credits will also be submitted electronically to NABP. Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: http://www.nabp.net/programs/cpe-monitor/cpe-monitor-service. To receive credit for your participation in this activity, all pharmacists must include their NABP e-Profile ID number, along with their date and month of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.

Please allow up to 30 days for your credit to appear on CPE Monitor.

Type of Activity: Knowledge

Published: March 31, 2016
Expires: March 31, 2017

Media: Internet

Fee Information: There is no fee for this educational activity.

Estimated time to complete activity: 30 minutes


Participants must complete the activity as described above in the Credit Designation Statement. To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of CE credit will be made available immediately. Click on View Certificate and print the CE statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test.


As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:

Val R. Adams, PharmD, FCCP, BCOP
Associate Professor
Pharmacy Practice and Science Department
College of Pharmacy
University of Kentucky
Lexington, Kentucky
Dr Adams reports serving on an advisory board for Teva.


In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The authors will inform the reader of when they discuss or reference an unapproved, unlabeled, or investigational use of therapeutic agent or biomedical device.


The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.


A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at gfarr@utasip.com. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.


The following is an interactive case simulation designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, an interactive case study, and a CPE post-test, and evaluation. All 3 sections must be completed to receive CPE credit. A statement of credit will be available online immediately following successful completion of the activity.


Please ensure the computer you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible.
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft Power Point, Flash Player & HTML5



Expanding Horizons in Immuno-Oncology: Health System Pharmacists' Perspectives –
Case 1: The New Immune Checkpoint Inhibitors: Toward a Cure for Metastatic Melanoma

Val R. Adams, PharmD, FCCP, BCOP